Terminated PHASE2 INTERVENTIONAL 2-arm NCT00926354

Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients

Phase II Open Study to Evaluate Safety and Efficacy of AS101 for the Treatment of Thrombocytopenia in Solid Tumor

Sponsor: BioMAS Ltd

Conditions Chemotherapy Induced Thrombocytopenia

Interventions AS101

Updated 5 times since 2017 Last updated: Jun 19, 2011 Started: Aug 31, 2009 Primary completion: Aug 31, 2010 Completion: Aug 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor's considerations

Other terminated trials from BioMAS Ltd

Atopic Dermatitis · Phase PHASE2 · Sep 2010

More terminations from BioMAS Ltd

Listed as NCT00926354, this PHASE2 trial focuses on Chemotherapy Induced Thrombocytopenia and remains terminated or withdrawn. Sponsored by BioMAS Ltd, it has been updated 5 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BioMAS Ltd

Data source: BioMAS Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kfar Saba, Israel